Nine of 12 patients treated in a double-blind manner with topical 1.0% lomustine had complete resolution of psoriatic plaques in four to six weeks. Local toxicity included cutaneous irritation with epidermal separation, hyperpigmentation, telangiectasia, and cutaneous pain and pruritus. Two patients developed temporary bone marrow suppression. At present, four of the 12 patients have received 18-month remissions.
Peck GL, Guss SB, Key DJ. Topical Lomustine in the Treatment of Psoriasis. Arch Dermatol. 1972;106(2):172-176. doi:10.1001/archderm.1972.01620110008002